DIA: Driving Insights to Action
Science:Life Sciences
“There are good reasons to explore the use of artificial intelligence in pharmacovigilance. There are an increasing number of sources of drug safety information, and efficient screening, processing, or evaluation of them would benefit from accurate automated methods,” explains Gerald Dal Pan, Director, Office of Surveillance and Epidemiology (OSE), CDER. “First, there’s the potential application of AI to the processing of case reports. Second, there’s the potential application of AI for assessing causality in a case report. Third, we’re exploring the use of AI in real-world data as part of the Sentinel Initiative.”
GPP Experts Explain Authorship Algorithm
"Dossier in the Cloud" Democratizing Global Access
DIA: A Place Where You Can Make a Difference
Autumn’s Leukemia Story: Regimens, Recovery, and Realizations
Retiring TGA Head Maps Australia’s Post-Pandemic Future
Patient Engagement: Evolution of Who Knows What, Part 2
Patient Engagement: Evolution of Who Knows What, Part 1
Australian Clinical Trials Alliance Part 2 – Future Projections
ANVISA Explains Innovative Online Optimized Assessment Project
Australian Clinical Trials Alliance Part 1 – Current Perceptions
Looking Back and Ahead: Translational Science Advances Impacting Patient Care
Rwanda Welcomes African Medicines Agency Home
Will Technology Solve the Research “People Problem”?
Why Trans/Nonbinary Research Benefits All Communities
Digital Revolutionizing Data-Driven Reimbursement
China Sets New Record for Local Drug Approvals in 2021
WHO Pilot Formalizes CSA Process to Assist Developers
Medication Errors Emerge as Global Patient Safety Issue
What We Are Missing by Not Including ”Who?”
Cancer Data Ecosystem Powering Moonshot Relaunch
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Speaking of Psychology